The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: A retrospective longitudinal cohort study

Drugs and Aging

Volumn 29, Issue 1, 2012, Pages 45-51

  Ma, Tsochiang ^a   Chang, Mu Hsin ^b   Tien, Liyun ^c   Liou, Yi Sheng ^d   Jong, Gwo Ping ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Atorvastatin; Elderly; Fluvastatin; HMG CoA reductase inhibitors; Hyperlipidaemia; Hypertension; Lovastatin; Pravastatin; Rosuvastatin; Simvastatin; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VASODILATOR AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; DYSLIPIDEMIA; FEMALE; HAZARD RATIO; HEALTH HAZARD; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NEW ONSET DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; RISK; TAIWAN;

EID: 84255173267     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11597250-000000000-00000     Document Type: Article

References (21)

1. Filippo CD, Cuzzocrea S, Rossi F, et al. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev 2006; 24: 77-87 (Pubitemid 46696918)
2. Jong GP, Chang MH, Tien L, et al. Antihypertensive drugs and new-onset diabetes: a retrospective longitudinal cohort study. Cardiovasc Drug Rev 2009; 27: 159-63
3. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-62 (Pubitemid 32105973)
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58 (Pubitemid 36398384)
5. Collins R, Armitage J, Parish S, et al., for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16
6. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure.NEngl J Med 2007; 357: 2248-61 (Pubitemid 350190755)
7. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-21 (Pubitemid 37205536)
8. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207
9. Sattar D, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative: meta-analysis of randomized statin trials. Lancet 2010; 375: 735-42
10. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003; 22: 151-4
11. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22 (Pubitemid 28248586)
12. Sasaki J, IwashitaM, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13: 123-9
13. Mascitelli L, Pezzetta F, Goldstein MR. Statins and risk of incident diabetes. Lancet 2010; 375: 2140-1
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
15. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881-92 (Pubitemid 44025043)
16. Coleman CI, Reinhart K, Kluger J, et al. The effect of statins on the development of new-onset type 2 diabetes: a metaanalysis of randomized controlled trials. Curr Med Res Opin 2008; 24: 1359-62 (Pubitemid 351741567)
17. Sheikh K. Statins and risk of incident diabetes. Lancet 2010; 375: 2139-40
18. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a metaanalysis. Diabetes Care 2009; 32: 1924-9
19. Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008; 149: 5136-45
20. Mascitelli L, Pezzetta F, Goldstein MR. Does intensive cholesterol lowering increase the risk of diabetes? Int J Clin Pract 2009; 63: 1808-9
21. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39 (Pubitemid 38924592)